Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid Inhibitor

1 Dec 2023

Abstract excerpt

studies and the 10-day monotherapy clinical study with single injections. The antiretroviral activity of Lenacapavir is unaffected by any mutation conferring resistance to older antiretrovirals. Lenacapavir is slowly released from the site of injection and this requires an initial coverage by its oral formulation (half-life: 10-12 days) in order to provide adequate pharmacokinetic exposure in the first days of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38075416
DOI: 10.53854/liim-3104-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid InhibitorPMID 38075416Read ↗

Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIVSemantic proximity Read ↗

Current and Novel Inhibitors of HIV ProteaseSemantic proximity Read ↗

Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisSemantic proximity Read ↗

The pharmacokinetics, pharmacodynamics and pharmacogenetics of Dolutegravir and Cobicistat in the treatment of HIVSemantic proximity Read ↗

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read ↗

Pharmacokinetic Parameters of HIV-1 Protease Inhibitors.Semantic proximity Read ↗

Covalent anti-HIV compound that induces HIV-1 capsid multimerization and degradation decomposes the viral coreSemantic proximity Read ↗

Design, synthesis and profiling of highly potent antivirals targeting emerging drug-resistant HIV-1 variantsSemantic proximity Read ↗

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.Semantic proximity Read ↗

Dolutegravir: an exciting new kid on the block.Semantic proximity Read ↗

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.Semantic proximity Read ↗

Cobicistat: Review of a Pharmacokinetic Enhancer for HIV InfectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.